No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Why Investors Shouldn't Be Surprised By Guilin Sanjin Pharmaceutical Co., Ltd.'s (SZSE:002275) Low P/E
Guilin Sanjin Pharmaceutical (SZSE:002275) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
Guilin Sanjin Pharmaceutical (002275.SZ) distributed 2.5 yuan per 10 shares in the first three quarters, with a record date of November 25th.
Guilin Sanjin Pharmaceutical (002275.SZ) announced that the company will implement the distribution of equity for the first three quarters of 2024, every 1...
Guilin Sanjin: Report for the third quarter of 2024
Guilin Sanjin Pharmaceutical (002275.SZ): The net income for the first three quarters was 0.384 billion yuan, a 3.28% year-on-year decrease.
Gelonghui October 29th | Guilin Sanjin Pharmaceutical (002275.SZ) announced the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 1.575 billion yuan, a year-on-year decrease of 3.49%; net income attributable to shareholders of the listed company was 0.384 billion yuan, a year-on-year decrease of 3.28%; net income after deducting non-recurring gains and losses was 0.347 billion yuan, a year-on-year decrease of 7.78%; basic earnings per share was 0.65 yuan per share.
Guilin Sanjin Pharmaceutical Co., Ltd. (SZSE:002275) Looks Inexpensive But Perhaps Not Attractive Enough